| Trial ID: | L4077 |
| Source ID: | NCT00696722
|
| Associated Drug: |
Placebo + Atazanavir
|
| Title: |
Effects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial Dysfunction
|
| Acronym: |
DM2ATV
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus Related Endothelial Dysfunction
|
| Interventions: |
DRUG: placebo + atazanavir|DRUG: atazanavir + placebo
|
| Outcome Measures: |
Primary: Acetylcholine induced vasodilation, following a 4 day treatment with either placebo or atazanavir | Secondary: heme oxygenase expression and activity, following a 4 day treatment with either placebo or atazanavir|assessment of vascular inflammation by determination of adhesion molecule levels, following a 4 day treatment with either placebo or atazanavir
|
| Sponsor/Collaborators: |
Sponsor: Radboud University Medical Center | Collaborators: Dutch Diabetes Research Foundation
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
16
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-06
|
| Completion Date: |
2009-03
|
| Results First Posted: |
|
| Last Update Posted: |
2010-01-26
|
| Locations: |
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, 6500, Netherlands
|
| URL: |
https://clinicaltrials.gov/show/NCT00696722
|
